// App-Quantinova.ai

: Single-Agent Ibrutinib vs Real-World (RW) Treatments for Patients with Chronic Lymphocytic Leukemia (CLL) and del11q: Adjusted Comparison of RESONATE-2TM and RESONATETM with RW Databases

Researchers

Presenter

  • Gilles Andre Salles

Principal Investigators

  • Evelyne Callet-Bauchu

  • Herv Besson

  • Margaret Doyle

  • Jamie Garside

  • Martin Spacek

  • Michael Doubek

Medical Centers

  • Laboratory of hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Universite Claude Bernard, Pierre Benite, France

  • Janssen EU HEMAR Statistics & Modelling,Beerse,Belgium

  • 7Janssen-Cilag EMEA Medical Affairs,Dublin,Ireland

  • Janssen EMEA HEMAR, High Wycombe, United Kingdom

  • General Teaching Hospital in Prague, Prague, Czech Republic

  • Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic

  • CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic

Locations

  • France

  • Belgium

  • Ireland

  • United Kingdom

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01722487

  • NCT01578707

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved